An observational study in Stroke, Stroke Acute and Endovascular Procedures, sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization. Enrolling by invitation at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization · Observational
The MEMENTO (MEchanical thrMobectomy NETwork for MENA TOgether) Registry is a multicenter, prospective observational study aiming to evaluate the effectiveness, safety, and cost-effectiveness of mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) due to large vessel occlusions (LVO) in the Middle East and North Africa (MENA) region. This interim analysis reports on the first 499 patients enrolled, assessing clinical outcomes, procedural details, and economic implications.
Detailed Description Stroke is a leading cause of morbidity and mortality worldwide, with a significant burden in the MENA region due to limited access to advanced stroke care therapies like mechanical thrombectomy (MT). The MEMENTO Registry seeks to collect real-world data on MT practices, outcomes, and accessibility in the MENA region to inform clinical practice and policy. The study includes AIS patients who underwent MT for confirmed LVO or medium vessel occlusion (MeVO), with or without prior intravenous thrombolysis (IV tPA), regardless of age, baseline NIHSS score, or time from symptom onset.
Data collected encompass demographics, clinical characteristics, imaging findings, procedural details, outcomes at discharge and follow-up, complications, and a cost-effectiveness analysis comparing MT to standard medical care (SMC). The primary outcome is functional independence at 90 days post-procedure, defined as a modified Rankin Scale (mRS) score of 0-2.
7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 160 across 1,729 observational studies indexed under Stroke.
Browse Stroke studies →Middle East North Africa Stroke and Interventional Neurotherapies Organization is the lead sponsor of 5 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients presenting with acute ischemic stroke due to LVO or MeVO at participating centers in the MENA region, who received MT as part of standard clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18 years and older (no upper age limit). Diagnosed with acute ischemic stroke due to confirmed large vessel occlusion (LVO) or medium vessel occlusion (MeVO).
Underwent mechanical thrombectomy (MT) with or without prior intravenous thrombolysis (IV tPA).
Pre-stroke modified Rankin Scale (mRS) score of 0-5. Consent to participate in the registry (by patient or legal representative).
Exclusion Criteria:
Absence of confirmed LVO or MeVO. Pre-stroke mRS score of 6. Known severe comorbid conditions precluding MT. Inability to obtain informed consent. Patients not treated with MT.
Functional Independence at 90 Days
Description: Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-2 at 90 days post-procedure.
Time frame: 90 days post-procedure
Proportion of Patients Achieving TICI Score ≥2b After MT
Proportion of patients achieving Thrombolysis in Cerebral Infarction (TICI) score ≥2b after MT. Scale Title: Thrombolysis in Cerebral Infarction (TICI) score Scale Range: 0 to 3 Outcome Interpretation: Higher scores indicate better outcomes, with a score of ≥2b representing successful reperfusion.
Time frame: Immediately post-procedure
Improvement in NIHSS Score from Baseline to 24 Hours and at Follow-up
Improvement in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours and at follow-up. Scale Title: National Institutes of Health Stroke Scale (NIHSS) Scale Range: 0 to 42 Outcome Interpretation: Lower scores indicate better outcomes, with a decrease in score representing improvement in stroke symptoms.
Time frame: Baseline, 24 hours, and up to 90 days
Symptomatic Intracerebral Hemorrhage (sICH) Rate
Incidence of symptomatic intracerebral hemorrhage (sICH) in patients post-mechanical thrombectomy (MT), defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria. sICH is identified when there is: Imaging Evidence: Any intracerebral hemorrhage (ICH) detected on neuroimaging (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]). Clinical Deterioration: A neurological worsening characterized by an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline or leading to death.
Time frame: Within 7 days post-procedure
All-Cause Mortality at 90 Days
Proportion of patients who have died from any cause by 90 days post-procedure.
Time frame: 90 days post-procedure
Complication Rate
Incidence of procedure-related complications (e.g., arterial dissection, vessel perforation).
Time frame: Immediately post-procedure up to 7 days
Incremental Cost-Effectiveness Ratio (ICER) per Quality-Adjusted Life Year (QALY) Gained
The cost-effectiveness of mechanical thrombectomy (MT) compared to standard medical care (SMC) will be assessed by calculating the Incremental Cost-Effectiveness Ratio (ICER). This involves measuring both costs and health outcomes: Costs: Using hospital billing records and resource utilization data. Effectiveness: Measuring QALYs using the EQ-5D-5L questionnaire, a standardized instrument for measuring health outcomes. ICER Calculation: Explaining that the ICER will be calculated by dividing incremental costs by incremental QALYs.
Time frame: From baseline (pre-procedure) through 90 days post-procedure, with economic modeling extended to a lifetime horizon (up to 20 years)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Middle East North Africa Stroke and Interventional Neurotherapies Organization